Mutations of ASXL1 gene in myeloproliferative neoplasms. - Wikidata - awgldk - TriplyDB

Mutations of ASXL1 gene in myeloproliferative neoplasms.

Mutations of ASXL1 gene in myeloproliferative neoplasms.

http://www.wikidata.org/entity/Q43456344

about

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications Molecular prognostic factors in cytogenetically normal acute myeloid leukemia JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?The evolving treatment paradigm in myelofibrosis Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs)Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?Mouse genome-wide association and systems genetics identify Asxl2 as a regulator of bone mineral density and osteoclastogenesis A novel BCR-ABL1 fusion gene with genetic heterogeneity indicates a good prognosis in a chronic myeloid leukemia case.Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.Immunomodulatory agents in myelofibrosis.Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis AKT is a therapeutic target in myeloproliferative neoplasms Integrated analysis of germline and somatic variants in ovarian cancer.Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population.Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer.JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.The JAK2 exon 12 mutations: a comprehensive review.Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms.Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.

P2860

Q24568313-468C8A15-E1E4-43A0-B96F-BF6094E9DD5D Q26768600-F4C6422D-3A58-43B2-A468-CD5D63D38653 Q26779960-A5232BCB-85DF-413D-98AC-FA8548CB0E5E Q26801380-352A8263-DB04-4573-B68A-A48EC8878AD3 Q26998811-8D6B1AE7-8F93-48D4-9E96-F3A3E6D9FC2A Q27012572-AB91EDE2-FC29-408B-82A2-D7A105B6BDC2 Q27021968-A02B2C7F-3186-4DF0-8021-6E863880A16F Q27687464-23E8FC2D-36FE-4026-A7F7-FCCC7CF48C8F Q27851565-6D54A353-8945-48E5-B8F4-1CEFE88D27BE Q27851679-E77F3187-C7AE-4B8D-B3E9-6CB6E9BCF354 Q27851909-997EDBC6-879A-438A-B93E-D67A0EB96C17 Q28084727-85AB89E8-DF0A-4FB7-A41A-EF695F4E04B9 Q28307278-F31EC519-D262-4A19-8FBF-F9227AD0CABC Q28387115-DB97F5AE-B5AD-4C01-9EBA-3B0795591B8B Q28593424-850D7BCE-C04F-48B3-9C78-5D3DF09ADD21 Q30152631-8E75AD8C-4648-4918-B31D-687559AC185A Q33393587-6D281A2E-CF13-478B-B132-1EE3280202D5 Q33401615-73A0222D-BB14-4644-8765-519AF5BA6B6E Q33406648-0A63F96B-C2ED-4932-8221-13166FE027B6 Q33413428-6428FD2F-D552-4CBA-A22F-A4EE10209A84 Q33558154-BCCB162A-194C-4959-AEEA-02508F9D9531 Q33595912-00F5C260-07C6-4195-BCD6-BA47F304F045 Q33623277-E457F99C-685B-48EF-9846-6E5BD1356A66 Q33630954-95E6C950-3473-4E08-A183-9692D93D99AF Q33697252-A6AAB191-6B42-45E8-8C4E-E4C126B1DC24 Q33701852-751301A1-9C95-40C3-BF0A-FA63C5875B8B Q33888064-EB13C005-DF79-4AC1-A732-2C01D833CBEC Q33892323-36CD937F-FE13-417F-A991-D38E9F3453E6 Q34129617-CE62E63E-19A8-464A-A11F-8FCDD47FF2F0 Q34134903-75DB8C5B-98CF-462C-B44B-14F5287C1768 Q34150008-FD0AB364-28AA-44DD-ACA6-A1FC523E9CAA Q34162729-A040629A-0106-4B1C-8A27-F61C9311F3C6 Q34166859-C2CA1720-4EF6-43C6-90FB-1303A35138B5 Q34192739-E0AD51D1-DA8D-4E39-8944-AD11C1EB84B0 Q34302770-D478092F-2223-4A43-A072-5F773C271774 Q34375134-2FF7C46E-E3B1-43F6-A5C3-FEDF8C028AED Q34417810-B868D191-9101-4B85-8F60-C4E63BFDC57A Q34419687-AB138A28-4F9B-473E-BAE7-B28C851C75E3 Q34562170-31B848AB-1EFD-40C1-AB1B-3E41D6BB36D2 Q34629928-84D3B36C-5637-476B-92DF-1622BC62BF5E

P2860

Mutations of ASXL1 gene in myeloproliferative neoplasms.

http://www.wikidata.org/entity/Q43456344

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Mutations of ASXL1 gene in myeloproliferative neoplasms.

@en

Mutations of ASXL1 gene in myeloproliferative neoplasms.

@nl

type

label

Mutations of ASXL1 gene in myeloproliferative neoplasms.

@en

Mutations of ASXL1 gene in myeloproliferative neoplasms.

@nl

prefLabel

Mutations of ASXL1 gene in myeloproliferative neoplasms.

@en

Mutations of ASXL1 gene in myeloproliferative neoplasms.

@nl

P1433

Q43456344-A2C0CF30-6F20-4880-9F92-0C72F5AF3FBF

P1476

Q43456344-3D81E7D6-DDCB-4798-89B0-C1E08C478A5D

P2093

Q43456344-072A07FC-73FF-41B9-8745-49E1F2E45D49

Q43456344-0981B5EB-A17D-43EA-B054-ADB7555D6EDB

Q43456344-8DB95D6D-0ED4-4AF0-9607-BDA4A067AECF

Q43456344-96E358B4-6D3B-45C7-AD9C-AFF73938205A

Q43456344-BC8AFD0E-B548-446B-8752-4B4572619FC3

Q43456344-BDA3688C-697A-41A2-BC6A-FD940863679C

Q43456344-D0F8FCED-B9D4-4277-A969-9BE64496D482

Q43456344-D83D269B-61DF-4F93-B1D7-F9C7CD29D827

Q43456344-F1FB8C85-2F50-4EEF-AD84-5CCB803E32C1

P2888

Q43456344-EF554054-6D16-4EAB-A419-8087E4CBCE1B

P304

Q43456344-9A512EA2-4A01-4761-8F0D-F13571E08984

P31

Q43456344-0EC4C499-7852-4A96-817E-E94ECF83A9C1

P356

Q43456344-2A4AEE70-0B63-41A3-B74F-DD48B8808388

P433

Q43456344-454D1E3F-46D2-4E38-8DC8-BDFBA9AFE769

P478

Q43456344-7647C0B3-63C1-46C9-A0E4-AEA79FF06375

P50

Q43456344-12B2D418-F6D2-4B90-B4BA-4B1AF25E41F5

Q43456344-6D033848-5C96-4A71-A229-3B17F27F8436

Q43456344-EB3A9C6E-E0CD-4B6C-B00A-03526517F833

P577

Q43456344-EE56DF35-8DF0-4B43-B2F5-9CD2FFD61112

P5875

Q43456344-45F8BD4D-E767-4078-A93B-580A5AAA717A

P6179

Q43456344-11123767-FFA2-4C75-805D-B3D4F9639271

P698

Q43456344-A4A11B57-F507-43B3-BF7E-46BD94138291

P356

P1433

P1476

Mutations of ASXL1 gene in myeloproliferative neoplasms

@en

P2093

A Murati

http://www.w3.org/2001/XMLSchema#string

J Adélaïde

http://www.w3.org/2001/XMLSchema#string

J Rey

http://www.w3.org/2001/XMLSchema#string

M Brecqueville

http://www.w3.org/2001/XMLSchema#string

M Chaffanet

http://www.w3.org/2001/XMLSchema#string

M J Mozziconacci

http://www.w3.org/2001/XMLSchema#string

N Carbuccia

http://www.w3.org/2001/XMLSchema#string

N Vey

http://www.w3.org/2001/XMLSchema#string

V Trouplin

http://www.w3.org/2001/XMLSchema#string

P2888

P304

2183-2186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2009.141

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

William Vainchenker

Daniel Birnbaum

Olivier Bernard

P577

2009-07-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26677064

http://www.w3.org/2001/XMLSchema#string

P6179

1041858819

http://www.w3.org/2001/XMLSchema#string

P698

19609284

http://www.w3.org/2001/XMLSchema#string